Summary
The product ARIMIDEX Anastrozole 1 mg tablets, manufactured by Unique Pharma, underwent independent testing for quality verification. The sample, identified by batch number UN66217 with an expiration date of March 2026, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis found the product contained 1.26 mg of Anastrozole per tablet, exceeding the labeled claim of 1 mg by 26%.
The testing process began on 22 April 2024, with the sample received on 28 May 2024, and the analysis completed on 2 June 2024. While this result demonstrates accuracy in dosing for the tested batch, it is important to assess consistency across all production batches to validate these findings. Independent, third-party testing of additional samples remains essential for comprehensive product evaluation.
This report is provided to promote educational awareness and harm reduction in the use of pharmaceutical products.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: ARIMIDEX Anastrozole 1 mg tablets
- Active Ingredient: Anastrozole
- Batch Number: UN66217
- Expiration Date: 03/2026
- Delivery Method: Oral tablets
Sample Acquisition and Testing
- Task Number: #43049
- Testing Ordered: 22 April 2024
- Sample Received: 28 May 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 1 mg per tablet (as stated on the label)
- Measured Concentration: 1.26 mg per tablet
- Accuracy: 126% (26% above the label claim)
- Variance: 26%
Verification Details
- Verification URL: https://janoshik.com/tests/43049_T5YG4H6GIPX8
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
The analysis confirms that the product is slightly overdosed, with a measured concentration of 1.26 mg of Anastrozole per tablet. However, since the sample was submitted and funded by the reseller Opitropin.EU, it is vital to critically assess the findings. Resellers may intentionally submit high-quality batches for analysis, which could result in outcomes that do not fully reflect broader product consistency. Independent testing of multiple batches by unaffiliated third-party laboratories is recommended to ensure accuracy and reliability across the product line.
Conclusion
The lab test confirms that the ARIMIDEX Anastrozole 1 mg tablets exceed the labeled claim by 26%, reflecting high-quality standards for this specific batch. Additional testing across various batches is encouraged to validate these findings and ensure consistent quality. This report is shared for educational purposes to support harm reduction and informed decision-making in pharmaceutical use.
Disclaimer
This report is intended solely for educational and harm reduction purposes. Reseller-submitted test results may involve inherent biases. To obtain a comprehensive product evaluation, readers are encouraged to seek independent third-party analyses. Always use this information responsibly.
